Thibert; Roch

Patent Applications and Registrations

Patent applications and USPTO patent grants for Thibert; Roch.The latest application filed is for "solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopen- tyl)methyl)urea hydrochloride and compositions, methods and kits related thereto".

Company Profile

6.11.19

Thibert; Roch - Mont-Royal CA
Thibert; Roch - Ville Mont-Royal CA
THIBERT; Roch - Quebec CA
THIBERT; Roch - Laval. Quebec CA
Thibert; Roch - Laval CA
Thibert; Roch - Outremont CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Grant 11,452,692 - Betancourt , et al. September 27, 2	2022-09-27
Solid Drug Form Of N-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopen- Tyl)methyl)urea Hydrochloride And Compositions, Methods And Kits Related Thereto App 20220162160 - Hunt, III; Stephen Warren ; et al.	2022-05-26
Compositions And Methods For Treating Disorders Ameliorated By Muscarinic Receptor Activation App 20220151933 - BETANCOURT; Aimesther ; et al.	2022-05-19
Solid Oral Formulations Of Amphotericin B App 20210369615 - HNIK; Peter ; et al.	2021-12-02
Compositions And Methods For Treating Disorders Ameliorated By Muscarinic Receptor Activation App 20210177762 - Betancourt; Aimesther ; et al.	2021-06-17
Compositions And Methods For Treating Disorders Ameliorated By Muscarinic Receptor Activation App 20210154146 - BETANCOURT; Aimesther ; et al.	2021-05-27
Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Grant 10,933,020 - Betancourt , et al. March 2, 2	2021-03-02
Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation Grant 10,925,832 - Betancourt , et al. February 23, 2	2021-02-23
Compositions And Methods For Treating Disorders Ameliorated By Muscarinic Receptor Activation App 20200289419 - BETANCOURT; Aimesther ; et al.	2020-09-17
Solid Drug Form Of N-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopen- Tyl)methyl)urea Hydrochloride And App 20200255372 - Kind Code	2020-08-13
Solid Oral Formulations Of Amphotericin B App 20200155583 - HNIK; Peter ; et al.	2020-05-21
Compositions And Methods For Treating Disorders Ameliorated By Muscarinic Receptor Activation App 20200101018 - BETANCOURT; Aimesther ; et al.	2020-04-02
Solid oral formulation of fenretinide Grant 10,512,619 - Betancourt , et al. Dec	2019-12-24
Solid oral formulation of fenretinide Grant 10,406,127 - Betancourt , et al. Sept	2019-09-10
Solid Oral Formulation Of Fenretinide App 20190117599 - BETANCOURT; Aimesther ; et al.	2019-04-25
Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopen- tyl)methyl)urea hydrochloride and compositions, methods and kits related thereto Grant 10,059,660 - Hunt, III , et al. August 28, 2	2018-08-28
Solid Drug Form Of N-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopen- Tyl)methyl)urea Hydrochloride And Compositions, Methods And Kits Related Thereto App 20170305843 - Hunt, III; Stephen Warren ; et al.	2017-10-26
Solid Oral Formulation Of Fenretinide App 20170189356 - BETANCOURT; Aimesther ; et al.	2017-07-06
Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopen- tyl)methyl)urea hydrochloride and compositions, methods and kits related thereto Grant 9,546,135 - Hunt, III , et al. January 17, 2	2017-01-17
Solid Drug Form Of N-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopen- Tyl)methyl)urea Hydrochloride And Compositions, Methods And Kits Related Thereto App 20160090354 - Hunt, III; Stephen Warren ; et al.	2016-03-31
Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid Grant 8,980,918 - Betancourt , et al. March 17, 2	2015-03-17
Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid App 20140255340 - Aimesther; Betancourt ; et al.	2014-09-11
Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid Grant 8,703,956 - Betancourt , et al. April 22, 2	2014-04-22
Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid App 20120282223 - BETANCOURT; Aimesther ; et al.	2012-11-08
Combination Therapy App 20100210611 - Thibert; Roch	2010-08-19
Aerosol powder formulation App 20070071692 - Thibert; Roch ; et al.	2007-03-29
Flavored taste-masked pharmaceutical formulation made using a one-step coating process App 20060228410 - Dumont; Hubert ; et al.	2006-10-12
Substituted 8-arylquinoline phosphodiesterase-4 inhibitors Grant 6,740,666 - Macdonald , et al. May 25, 2	2004-05-25
Substituted 8-arylquinoline phosphodiesterase-4 inhibitors App 20020143032 - Macdonald, Dwight ; et al.	2002-10-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.